首页良性前列腺增生治疗及预后证据详情

Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia

原文:2020年 发布于 Int Urol Nephrol 52卷 第6期 999-1008 浏览量:701次 原文链接

作者: Tanneru K. Gautam S. Norez D. Kumar J. Alam M. U. Koocheckpour S. Balaji K. C. Joseph C.

作者单位: Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA. Department of Biostatistics, University of Florida, Jacksonville, FL, USA. Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA. joseph.costa@jax.ufl.edu.

归属分类: 良性前列腺增生治疗及预后证据

DOI: 10.1007/s11255-020-02408-y

关键词: Follow-Up Studies Humans Male Prostatic Hyperplasia Time Factors Urethra Urologic Surgical Procedures Male/methods Bph Luts Pul Prostatic urethral lift Urolift

文献简介

BACKGROUND: Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results. METHODS: We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes. RESULTS: Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Q(max)) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups. CONCLUSION: PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.

热门文献